Genomic copy number instability test

About Insight Molecular Diagnostics

iMDx is dedicated to advancing precision medicine by making critical molecular diagnostic tests more accessible in transplantation and oncology. The company has pivoted under CEO Josh Riggs to decentralize its testing approach, offering both clinical assays and research-use-only kits. With a leadership team combining decades of diagnostics experience, iMDx is developing non-invasive monitoring tools for organ rejection and cancer treatment response, targeting two of the fastest-growing areas in diagnostics.

Therapeutic Areas